Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.

Participants needed: 18
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: M. Peter MarinkovichUpdated: May 5, 2026Locations: 1
Eligibility criteria

For DEB patients (aged 12 years or older): DEB confirmed with mutation analysis... [+4]

Linear IgA dermatosis-like EBA or other autoimmune blistering diseases (includin... [+16]

Read more
Status: Recruiting

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

Participants needed: 8
Trial details
Phase: Phase 1, Phase 2Age: 6+Biological sex: AllType: InterventionalSponsor: M. Peter MarinkovichUpdated: May 5, 2026Locations: 1
Eligibility criteria

Diagnosis of generalized Recessive dystrophic epidermolysis bullosa (RDEB) demon... [+5]

History of thrombotic event(s) [+3]

Read more